Bernard Gilly
Chairman and co-founder of Pixium Vision


Lloyd Diamond
Chief Executive Officier of Pixium Vision

The mission of Pixium Vision is to create a world of bionic vision for those who have lost their sight. Age-related macular degeneration (AMD) is the leading cause of severe vision loss and legal blindness in people over the age of 65 in North America and Europe. The global impact is significant with current projected estimates of 196 million people worldwide living with AMD and expected rapid growth due to ageing population. Around 1,000 new patients are diagnosed every day in Europe and U.S. There are two forms of advanced AMD: the wet form, where treatment like anti-VEGF injections slows down the disease progression, and the dry form that is most frequent, where there is currently no curative treatment available. More than 5 million patients are afflicted with advanced dry AMD, also referred to as Geographic Atrophy.

Pixium Vision has addressed this important medical and societal need by developing PRIMA System, which is designed to restore sight in patients blinded by retinal dystrophies especially atrophic dry AMD. It features a miniaturized and totally wireless sub-retinal implant and augmented reality glasses. The PRIMA implant is placed under the retina via a minimally invasive surgical procedure, it acts like an array of tiny solar panels powered by pulsed near-infrared light emitted from a miniature projector transmitting images captured on a mini camera. The camera and projector technologies are integrated into augmented reality glasses, which together with the PRIMA implant, make the PRIMA System.

Pixium Vision is currently conducting in France and in the United States, two feasibility clinical trials with the PRIMA System, for patients with severe vision loss due to retinal degeneration caused by the dry atrophic form of AMD Recruitment has been completed in France with 12 months’ interim results that have recently been published

Pixium Vision intends to commercialize the PRIMA System by first targeting Dry-AMD and secondly other retinal dystrophies like Retinitis Pigmentosa (RP).

Pixium Vision, with its novel breakthrough PRIMA System comprising a miniaturized and wireless sub-retinal next generation implant, addressing a significant unmet need where no treatment is available to date, is in a unique position to significantly contribute to the restoration in the form of artificial vision to people who have lost sight, in order to enable them to live more autonomously with an improved quality of life.


Share Information


Financial Calendar


In the News


Scientific Publications